To determine the effects of combination treatment of the AKT/mTOR inhibitor VS-5584 and the WNT inhibitor ICG-001 on human AML cell proliferation, we first treated TF1-pEGFP and TF1-hPRL3 cells with various concentrations of VS-5584 and ICG-001 as single drug and in combination and monitored cell proliferation by CTG assay. Here, MTOR is linked to acute myeloid leukemia.